Cellectis S.A. CLLS
Biotechnology: Pharmaceutical Preparations · IPO 2015 · data as of November 13, 2026
Cellectis S.A. (CLLS) is a healthcare company listed in the US with a market value of about $119M. In the twelve months to June 30, 2026 it had revenue of $57M and net income of -$65M, a net margin of -115.4%.
Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is future growth (4/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of 6% a year, a 5-year average ROIC of -57%.
About Cellectis
Cellectis is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2015. Revenue went from $56M in 2016 to $80M in 2025, growth of about 3.9% a year. It was profitable in 0 of the last 10 years in our data.
Score: 1.0 / 5
Checks passed
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
- 5-year revenue growth above 8% a year
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $57M | $80M | $49M | $9M | $26M | $39M | $60M | $23M | $21M | $34M | $56M |
| Net income | -$65M | -$68M | -$37M | -$101M | -$106M | -$114M | -$81M | -$102M | -$79M | -$99M | -$67M |
| Free cash flow | -$45M | -$42M | $20M | -$26M | -$90M | -$123M | -$124M | -$82M | -$73M | -$55M | -$46M |
| EPS (diluted) | $-0.65 | $-0.67 | $-0.37 | $-1.01 | $-1.06 | $-1.14 | $-0.81 | $-1.02 | $-0.78 | $-0.99 | $-0.67 |
| Net margin | -115.4% | -84.9% | -74.7% | -1099.3% | -412.6% | -295.9% | -136.1% | -444.1% | -367.2% | -294.7% | -119.2% |
| ROIC | — | -43.3% | -45.5% | -90.8% | -60.1% | -46.8% | -14.9% | -39.2% | -25.7% | -35.0% | -24.7% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 4 analysts is $4.45, 277% above the current price; targets range from $1.30 to $8.00; the consensus rating is “Buy”; expected EPS is $-1.25 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Cellectis pay a dividend?
Not currently.
Is Cellectis a good stock to buy?
We do not give buy or sell advice. Cellectis scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.